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Silmmary A double-blind, randomized, crossover study was conducted to compare the efficacy and safety of
high-dose dexamethasone (Protocol D) with a combination of dexamethasone, metoclopramide and
diphenhydramine (Protocol DMD) in the management of chemotherapy-induced nausea and vomiting in
cancer patients. All entered patients had received no prior chemotherapy. During the study chemotherapy was
administered on an inpatient basis. The majority of patients (94%) were treated with cytotoxic drugs of
significant emetogenic activity and 40% of the study group received cis-platin-containing combinations.
Of the 60 evaluable patients, complete antinausea and antivomiting effects of D were observed in 30 (50%)
and 34 (57%), respectively and of DMD in 17 (28%) and 26 patients (43%) respectively. The difference was
not statistically significant (P=0.09 and 0.24, respectively). Lack of significant difference between the two
regimens was demonstrated irrespective of the administered cytotoxic drugs. The DMD protocol caused more
adverse reactions than D. While 27 patients (45%) experienced no side effects from D, only 14 (24%)
remained free of complications due to DMD (P=0.001). Furthermore, DMD produced more sedation,
insomnia, headache, diaphoresis, dizziness and diarrhoea than the D regimen. In addition it gave rise to more
adverse effects on appetite and activity. Upon direct questioning, 37 patients (62%) expressed a preference for
D, 14 (23%) preferred DMD and 9 (15%) found no difference between the two regimens.
We conclude that, while the short DMD protocol has an antiemetic activity equivalent in its effectiveness
to D, its associated adverse reactions would minimize its usefulness. Therefore, further investigations should
be conducted to find a safer and more potent combination of antiemetics suitable for therapy in an outpatient
setting.
Nausea and vomiting are the most common and potentially
grave complications of anticancer therapy (Laszlo & Lucas,
1981; Morran et al., 1979; Seigel & Long, 1981). Moreover,
emesis is an important limiting factor in the administration
of cytotoxic therapy (Seigel & Long, 1981). Total prevention
of chemotherapy-induced nausea and vomiting is paramount
in improving patients' acceptance of cytotoxic drugs.
Various groups of antiemetics with varying degree of
efficacy and modes of action have been tested (Laszlo, 1983;
Moertel & Reitemeier, 1969; Moertel et al., 1963; Wampler,
1983). Dexamethasone has been shown to exhibit significant
antiemetic activity in the past few years (Aapro & Plezia,
1983; Cassileth et al., 1983,1984; Markman et al., 1984).
Recently also, in a randomized, double-blind, crossover
study, we demonstrated conclusively that high-dose dexa-
methasone is more effective as an antiemetic and safer than
high-dose metoclopramide in patients who are mainly
receiving non-cis-platin emetogenic chemotherapy (Ibrahim
et al., 1986). However, the dosages and schedule of the
antiemetics used in that trial were not suitable for outpatient
management.
The administration of combinations of antiemetic drugs
which would act at different receptor sites should improve
their antiemetic potential through complete neuroreceptor
blockade (Bruera et al., 1983; Krebs et al., 1985; Mason et
al., 1982; Morran et al., 1979). Furthermore, combining two
or more antiemetics should minimise the adverse effects
produced by the constituent agents given singly in higher
doses. The efficacy and safety of a short course of the
combination of dexamethasone, metoclopramide and diphen-
hydramine (Protocol DMD) have been demonstrated
recently (Kris et al., 1985). However, the DMD regimen has
never been tested in a double-blind and randomized trial
against the well established antiemetic protocols.
We now present the outcome of a randomized, double-
blind, crossover study comparing the effectiveness of high-
dose dexamethasone (Protocol D) with a short course of
DMD. This short-course combination was also employed to
determine its suitability for future outpatient use. The
inclusion of diphenhydramine was intended to potentiate the
antiemetic effect through blocking of histamine receptors in
the brain stem (Peroutka & Snyder, 1982), and to counteract
any extrapyramidal reactions induced by metoclopramide
(Allen et al., 1983; Kris et al., 1983).
Materials and methods
From April 1985 to August 1986 patients with histologically
confirmed cancer who were receiving inpatient chemotherapy
for the first time were subjected to the study. Only those
who had a performance status of 70% or more on the
Karnofsky scale were included. We excluded from the trial,
patients above the age of 70, patients who had anticipatory
vomiting before chemotherapy, and those who had absolute
or relative contraindications to the use of steroids. A written
consent was obtained from all patients participating in the
study.
A randomized, double-blind, crossover design was used in
which each patient served as his or her own control. While
patients were randomly assigned, a balanced assignment
between the arms was maintained throughout the study.
During two consecutive courses of the same chemothera-
peutic regimen given in the same dosage, each patient was
randomly assigned to receive either high-dose dexamethasone
alone or dexamethasone combined with metoclopramide and
diphenhydramine in the first course and during the second
course of chemotherapy, the alternate antiemetic treatment
was administered. A minimum period of 21 days between the
two courses was allowed to eliminate any carryover effect of
either the cytotoxic or antiemetic.
Dexamethasone (20mg) was administered as an i.v.
'piggyback' over a 15min period beginning 30min before
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chemotherapy and 10mg at 1.5, 3.5, 5.5 and 8.5h after
chemotherapy (protocol D). The combination regimen
(protocol DMD) was given as follows: dexamethasone
(20mg) as an i.v. piggyback over a 15min period beginning
30min before chemotherapy, metoclopramide (3mgkg-1) as
an i.v. piggyback over a 15min period beginning 30min
before chemotherapy and repeated in the same dose 2h after
initiation of therapy, and diphenhydramine (50mg) i.v.
30min before chemotherapy. Only clear fluids by mouth
were allowed during the initial 12h of the trial. No other
drugs or antiemetics were given 24h before or after the start
of the chemotherapy regimen.
Prior to the administration of each arm of the study, each
patient was assessed for his or her baseline status in the 24h
period before chemotherapy. Treatment was postponed if
normal baseline status was not established. The identity of
the given antiemetic drugs was withheld from both the
patient and the person evaluating the response. In addition
to the baseline evaluation, each patient was evaluated 24h
after the chemotherapy administration.
Nausea was graded as follows: 0 (none), 1 (mild-tolerable,
no interference with activity), 2 (moderate-tolerable,
interference with activity), 3 (severe-intolerable, bedridden).
Vomiting was graded according to the number of emetic
episodes: 0 (none), 1 (mild <5), 2 (moderate, 5-10), 3
(severe, >10). Activity during the trial was graded as
follows: 0 (normal activity), 1 (mild impairment of activity),
2 (moderate-severe impairment of activity). The patient's
appetite was also graded as follows: 0 (normal appetite), 1
(mild impairment due to symptoms), 2 (moderate-severe
impairment due to symptoms). Any sedative effect of
antiemetics was evaluated according to the following grades:
0 (none), 1 (mild, lethargic, arousable by verbal stimuli,
completely oriented), 2 (severe, arousable only by physical
stimuli but disoriented). Patients were assessed for the side
effects of antiemetics such as: chills, diaphoresis, diarrhoea,
headache, dizziness, hypotensive symptoms, ataxia,
hallucinations, euphoria, extrapyramidal manifestations or
any other symptoms. After the second antiemetic regimen,
patients were asked to express their preference for the
antiemetic which they would receive with their future
therapy. Only after the second part of the trial was the
identity of the antiemetic revealed.
In the statistical analysis, the chi-square test of
homogeneity was used to evaluate independent samples.
McNemar's test was used to evaluate paired data
(McNemar, 1955).
Results
Sixty-two patients were randomly assigned with a balanced
entry to the two arms of the study. Two patients were
excluded after receiving only one antiemetic protocol for the
following reasons: one patient (DMD protocol) developed
fatal progression of his disease and the other (D protocol)
was lost to follow-up. The remaining 60 patients were
evaluated for adverse reactions and antiemetic response
(Table I). The various chemotherapeutic agents and drug
combinations used were classified into 3 groups using a
classification modified from that proposed by Sallen et al.
(1980). Table II shows the drug classifications and the
number ofpatients in each class.
Table III illustrates the antiemetic response to D and
DMD protocols. Thirty patients (50%) did not experience
nausea with D, while 17 patients (28%) had no nausea
during DMD therapy. The difference was not statistically
significant (P=0.09). Regarding the antivomiting effect, 34
(57%) and 26 (43%) patients were protected completely
against vomiting by protocols D and DMD respectively.
However, the difference was not significant (P =0.24).
Separate analysis based on classification of emetogenic
activity has also failed to demonstrate a significant difference
Table I Characteristics of the 60 evaluable patients
No. ofpatients
Age in years
Median
Range
Performance status
70%-80%
80%-90%
90%-100%
Type of cancer
Non-Hodgkins'
Breast
Lung
Ovary
Sarcoma
Head & neck
Hodgkin's
Other
Table II Classification of chemotherapeutic
their emetogenic activity
60
41
(14-70)
No. ofpatients
35
17
8
No. ofpatients
17
10
8
5
5
5
4
6
agents according to
No. of
patients (%)
A. Greatest emetogenic activity:
Combinations of agents including cis-platina,
doxorubicin, cyclophosphamide
(<1000mgm-2), or nitrogen mustard 49 (82%)
B. Moderate emetogenic activity:
Combinations of agents including high-dose
methotrexate, cyclophosphamide
(> I1000mgm -2), or mitomycin-C 7 (12%)
C. Least emetogenic activity:
Single agents including high-dose methotrexate,
cyclophosphamide or doxorubicin 4 (6%)
'24 patients had cis-platin-containing combinations.
Table In Antiemetic response to dexame-
thasone (D) and dexamethasone, metoclo-
pramide and diphenhydramine (DMD)
Nauseaa
DMD
0 1 2
0
1
D 2
3
Total
0
1
D 2
3
Total
3 Total
12 5 10 3 30
4 9 4 2 19
1 3 3 1 8
0 1 1 1 3
17 18 18 7 60
(4= 10.95, P=0.09)
Vomiting
DMD
0 1 2 3 Total
22 5 4
2 5 6
2 2 2
0 1 2
26 13 14
(X6=7.95, P=0.24)
3
0
2
2
7
34
13
8
5
60
aNausea: 0 (none), 1 (mild-tolerable, no
interference with activity), 2 (moderate-
tolerable, interference with activity), 3 (severe-
intolerable, bedridden); bVomiting: 0 (none), 1
(mild, fewer than 5 episodes), 2 (moderate, 5-
10), 3 (severe, more than 10). Each cell
represents the point response of the patients to
D and DMD. For example, with respect to
nausea 12 patients had no nausea to both
protocols, whereas 5 had no nausea to D but
mild nausea to DMD.
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between the two antiemetic protocols. There was no
significant correlation between the antiemetic response and
patients' sex. Evaluation of the 24 patients who had received
cis-platin-containing combinations showed a trend in favour
of D, however, the difference was not statistically significant
(P values for the antinausea and anti-vomiting activities were
0.059 and 0.071 respectively).
The side effects of both protocols were also analyzed.
Table IV shows that DMD caused varying degrees of
sedation and produced adverse effects on activity and
appetite in a significantly greater number of patients than D
(P=0.002, 0.01, and 0.01 respectively). It was also noted
that while 27 patients (45%) experienced no side effects due
to D, only 14 patients (24%) were free from complications
during DMD therapy (P=0.001). The other adverse
reactions of both regimens are shown in Table V. While
there were no metoclopramide-related extrapyramidal
manifestations, headache, dizziness and diarrhoea occurred
Table IV Side effects of dexamethasone (D)
and dexamethasone, metoclopramide, diphen-
hydramine (DMD)
more frequently during DMD antiemetic therapy. Of the 29
patients who developed diarrhoea during DMD protocol,
only 10 had combinations containing cis-platin while all the
5 patients who experienced loose bowel motions with the D
regimen received cis-platin as a part of their cytotoxic drug
therapy.
The antinausea and antivomiting activities as well as the
side effects of D and DMD were not affected by the order in
which they were administered.
On direct questioning, 37 patients (62%) expressed a
preference for D protocol, 14 (23%) preferred DMD, and 9
(15%) experienced no difference. This pattern of preference
was not influenced by the order in which the antiemetic
protocols were administered. For patients who received D
regimen first, 20 patients (67%) preferred D, 6 (20%)
favoured the DMD combination, and 4 (13%) found that
the two protocols were equal. On the other hand, for
patients started on DMD, 17 (57%) favoured D protocol, 8
(27%) preferred DMD, and 5 (16%) could not appreciate
any dissimilarity.
Discussion
Effect on activitya
DMD
0 1 2
0
1
D 2
Total
0
1
D 2
Total
0 12
1 8
D 2 0
Total 20
Total
17 14 9 40
6 3 3 12
1 7 0 8
24 24 12 60
(x2=11.2, P=0.01)
Effect on appetiteb
DMD
O 1 2 Total
15 14 13 42
7 3 3 13
2 1 2 5
24 18 18 60
(3=11.4, P=0.01)
Sedative effectc
DMD
O 1 2 Total
18
8
0
26
8
3
3
14
38
19
3
60
(X = 14.85, P=0.002)
aActivity: 0 (normal), 1 (mild impairment), 2
(moderate-severe impairment); bAppetite: 0
(normal), 1 (mild impairment), 2 (moderate-
severe impairment); cSedation: 0 (none), 1
(mild), 2 (severe).
Table V The main side effects of dexamethasone
(D), and dexamethasone, metoclopramide, and
diphenhydramine (DMD)
Side effect D DMD P
Yes No Yes No
Hallucinations 0 60 0 60 NS
Chills 0 60 2 58 NS
Euphoria 4 56 2 58 NS
Diaphoresis 2 58 21 39 <0.01
Insomnia 10 50 27 33 <0.01
Headache 12 48 32 28 <0.01
Dizziness 8 52 27 33 <0.01
Diarrhoea 5 55 29 31 <0.01
The results of this double-blind, crossover, randomized trial
demonstrate clearly again that high-dose dexamethasone (D)
is an effective antiemetic agent for patients receiving chemo-
therapy of high emetogenic potential. Effective antinausea
and antivomiting activities of 50% and 57% respectively in
this study are virtually identical to the 48% and 58% shown
in our previous trial with this drug (Ibrahim et al., 1986).
On the other hand, the employment of the antiemetic
combination of dexamethasone, metoclopramide and diphen-
hydramine (DMD) prevented nausea and vomiting in 28%
and 43% of subjects. However, the difference between the
efficacy of the two regimens was not statistically significant.
Furthermore, no significant difference could be demonstrated
between the two regimens in relation to the employed
emetogenic cytotoxic drugs. However, a trend - though was
not significant - in favour of D was noted in patients who
received cis-platin-containing combinations.
In contrast to our findings, Kris et al. (1985) obtained
effective antiemesis in 81% of their patients treated with an
identical dose schedule of DMD. The discrepancy between
these two results can be explained by differences in relevant
variables. First, our subjects were younger with a median age
of 41 years compared to 55 years in the trial of Kris and co-
workers. Thus age may be an important factor as it has been
shown that elderly patients are more sensitive to the
antiemetic effects of metoclopramide (Meyer et al., 1984).
Secondly, the differences in the two trial populations, study
designs, chemotherapeutic regimens and criteria for
evaluating response also provide additional explanations for
the disparate re.sults.
It had been noted previously that high-dose dexame-
thasone is a safe antiemetic (Cassileth et al., 1984; Ibrahim et
al., 1986). Our findings reinforce this important observation.
On our D regimen, 38 patients (63%) were free from any
sedative effects while 40 (67%), and 42 (70%) did not
experience any adverse changes in level of activity and
appetite respectively. Furthermore, 27 subjects (45%) did not
suffer from any complications during the administration of
the drug. DMD caused significantly more frequent side
effects than D. Using an identical DMD protocol, Kris et al.
(1985) reported mild sedation (which occurred in 79% of
their subjects) and diarrhoea as the only harmful effects. In
contrast, in our present study mild to severe sedation was
observed in 67% of the patients. Somnolence induced by
antiemetics may be advantageous as it may make the act of
vomiting more tolerable (Blandford et al., 1979; Krebs et al.,
1985). On the other hand, sedation may not only increase
the risk of aspirating vomitus but may also pose
unacceptable obstacles for ambulatory patients.ANTIEMETIC EFFICACY OF HIGH-DOSE DEXAMETHASONE 311
Diarrhoea was also a frequent complication of our DMD
regimen for it occurred in 29 patients (48%), 19 of whom
did not receive cis-platin as part of their anticancer therapy.
Though cis-platin can cause significant diarrhoea (Gralla et
al., 1981; Strum et al., 1982) it cannot be incriminated as the
responsible agent for the diarrhoea in the majority of those
affected. It is well established also that diarrhoea frequently
complicates high-dose i.v. metoclopramide therapy (Strum et
al., 1984). Thus, Kris et al. (1985) in their series of open
label consecutive trials on emesis control, demonstrated a
marked fall in the incidence of diarrhoea from 42% with
metoclopramide alone to only 5% when this drug was
combined with dexamethasone and diphenhydramine (DMD
protocol) in the same doses as in our study. In another
previously published study on patients receiving cis-platin,
the addition of dexamethasone to the high-dose metoclo-
pramide was also associated with marked reduction in the
incidence of the diarrhoea (6%) as compared with during
high-dose metoclopramide plus placebo (21%) (Allan et al.,
1984). The marked discrepancy between our data and those
quoted from other studies regarding the incidence of
diarrhoea when dexamethasone is combined with metoclo-
pramide, is difficult to explain. Difference in the study
populations, chemotherapy regimens, and the definition and
method of assessment of the degree and frequency of
diarrhoea are not adequate explanations for such widely
divergent results.
The design of our study did not permit a separate
evaluation of the antiemetic properties of diphenhydramine.
However, its inclusion in the DMD protocol succeeded in
protecting patients against adverse extrapyramidal reactions
which are known to occur with high-dose metoclopramide
(Gralla et al., 1981; Ibrahim et al., 1986; Strum et al., 1984).
Our experience with the short-course DMD regimen does
not support the hypothesis that the use of combination
antiemetics with different mode of actions is necessarily safer
and more effective than a single-agent with known
antiemetic potential. The previously reported efficacy and
safety of DMD Kris et al. (1985), could not be confirmed in
our study. Thus, the short-course advantage of DMD which
makes this protocol attractive for use in outpatients is
almost nullified by increased adverse effects which would be
even more intolerable in an outpatient environment.
Though it has been shown that there is a relative lack of
dose response relationship for dexamethasone (Drapkin et
al., 1982), the optimal dose of this drug has yet to be
determined. Therefore, it is possible that a DMD dose-
schedule in which dexamethasone is increased and given
orally and more frequently, while the dose of metoclo-
pramide is reduced and that of diphenhydramine is left
unaltered, might prove more effective and as safe as high-
dose dexamethasone alone. On the other hand, a marked
reduction in the metoclopramide dose might have an adverse
influence on the antiemetic potency of the combination. A
higher dose schedule of all the constituent agents would
almost certainly be associated with a greater incidence of
unacceptable harmful effects. Therefore, the need for
evaluation of other antiemetic regimens which are not only
suitable and convenient but also safe for outpatient use is
urgent.
The authors acknowledge the expert assistance of Dr Mohamed
Naguib.
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